HC Wainwright Has Positive Estimate for Precigen Q3 Earnings

Precigen, Inc. (NASDAQ:PGEN) – Analysts at HC Wainwright boosted their Q3 2026 earnings estimates for shares of Precigen in a research report issued on Wednesday, August 5th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of $0.05 for the quarter, up from their prior estimate of $0.01. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Precigen’s current full-year earnings is ($0.02) per share. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.14 EPS.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The company had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.98 million. Precigen had a negative net margin of 183.98% and a positive return on equity of 423.75%. The company’s revenue was up 6322.7% on a year-over-year basis.

PGEN has been the subject of a number of other research reports. Citigroup reissued an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Citizens Jmp raised their price target on shares of Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Finally, Wall Street Zen lowered Precigen from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $14.50.

Precigen Stock Performance

PGEN opened at $6.91 on Friday. The firm’s fifty day simple moving average is $5.17 and its two-hundred day simple moving average is $4.48. Precigen has a 52-week low of $1.70 and a 52-week high of $7.23. The company has a market cap of $2.46 billion, a price-to-earnings ratio of -6.64 and a beta of 1.02. The company has a quick ratio of 4.12, a current ratio of 4.58 and a debt-to-equity ratio of 2.15.

Insider Buying and Selling at Precigen

In other Precigen news, COO Rutul R. Shah sold 33,772 shares of Precigen stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $6.50, for a total transaction of $219,518.00. Following the sale, the chief operating officer owned 497,751 shares of the company’s stock, valued at $3,235,381.50. The trade was a 6.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Harry Jr. Thomasian sold 100,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.06, for a total transaction of $606,000.00. Following the sale, the chief financial officer directly owned 254,535 shares of the company’s stock, valued at $1,542,482.10. The trade was a 28.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 956,500 shares of company stock worth $5,248,371. Company insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

A number of hedge funds have recently bought and sold shares of the business. SCS Capital Management LLC purchased a new position in Precigen in the 2nd quarter worth approximately $244,000. Bank of New York Mellon Corp purchased a new stake in shares of Precigen in the second quarter valued at approximately $2,705,000. State of Wyoming purchased a new stake in shares of Precigen in the second quarter valued at approximately $181,000. GSA Capital Partners LLP purchased a new stake in shares of Precigen in the second quarter valued at approximately $667,000. Finally, Royal Bank of Canada increased its holdings in shares of Precigen by 102.6% in the first quarter. Royal Bank of Canada now owns 10,714 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 5,426 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company’s stock.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Strong Q2 performance and profitability: Precigen reported that PAPZIMEOS revenue reached $53.1 million in the second quarter, roughly doubling sequentially. The company also achieved profitability, while earnings-call coverage highlighted a 145% increase in revenue. These results support the view that PAPZIMEOS is becoming a meaningful commercial product. Precigen Q2 2026 Earnings Call Highlights
• Positive Sentiment: Regulatory and commercial catalysts: FDA approval of PAPZIMEOS for recurrent respiratory papillomatosis, along with seven years of U.S. market exclusivity, strengthens the product’s revenue outlook. Potential European approval and expansion of Precigen’s AdenoVerse Immunotherapy platform—including PRGN-2009—could provide additional growth opportunities. Precigen Strong Buy and PAPZIMEOS Outlook
• Positive Sentiment: Analyst estimates moved higher: HC Wainwright reiterated its Buy rating and $18 price target, raising its FY2027 EPS forecast to $0.44 from $0.34. Estimates for Q4 2026 and each quarter of 2027 were also increased, while the FY2030 forecast rose to $1.49 from $1.44. These revisions signal greater confidence in the company’s earnings trajectory. HC Wainwright Reiterates Buy Rating for Precigen
• Neutral Sentiment: Unusually large options activity attracted attention, but the available report does not identify whether the transactions were bullish or bearish. Precigen Unusually Large Options Trading
• Negative Sentiment: One forecast was trimmed: HC Wainwright reduced its FY2028 EPS estimate slightly to $0.71 from $0.72, a minor offset to the broader upward revisions.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.